openPR Logo
Press release

Deadline on August 20th upcoming in Lawsuit for Investors in Teva Pharmaceutical Industries Limited (NYSE: TEVA)

08-14-2019 08:08 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on August 20, 2019 in the lawsuit for certain investors in Teva Pharmaceutical Industries Limited.

A Deadline is coming up on August 20, 2019 in the lawsuit for certain investors in Teva Pharmaceutical Industries Limited.

The Shareholders Foundation announced that a deadline is coming up on August 20, 2019 in the lawsuit filed for certain investors of Teva Pharmaceutical Industries Limited (NYSE: TEVA over alleged securities laws violations by Teva Pharmaceutical Industries Limited.

Investors who purchased shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA) have certain options and there are strict and short deadlines running. Deadline: August 20, 2019. NYSE: TEVA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Eastern District of Pennsylvania the plaintiff alleges that the defendants made false and/or misleading statements denying that Teva “engaged in any conduct that would give rise to liability” in various antitrust proceedings and investigations that enveloped the company. In truth, and as Defendants failed to disclose to investors, (i) contrary to its public denials, Teva had in fact engaged in a vast, industry-wide price-fixing scheme and other collusive misconduct since at least 2012; (ii) Teva was not only a participant, but the company at the heart of the anticompetitive scheme; and (iii) several Teva employees had such deep involvement in the scheme that they would ultimately be named personally as defendants in a sweeping civil enforcement action filed by the AGs of virtually every state in the nation.

Those who purchased shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on August 20th upcoming in Lawsuit for Investors in Teva Pharmaceutical Industries Limited (NYSE: TEVA) here

News-ID: 1822392 • Views:

More Releases from Shareholders Foundation

Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to recover losses
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements. Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover losses
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc.. Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Malvern, PA based Ocugen, Inc., a
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) should contact the Shareholders Foundation in connection with Lawsuit
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp. Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV
Investigation announced for Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) over possible Violations of Securities Laws
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false

All 5 Releases


More Releases for Teva

US Generic Drug Market 2021 Research and Clinical Analysis- Teva, Mylan, Actavis …
The report presents an in-depth assessment of the US Generic Drug Market including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for US Generic Drug from 2021 till 2026. The report covers the pre COVID-19 historic data, impact of COVID-19 and post-COVID-19 (Corona Virus) impact on various regions
Lawsuit filed for Investors in shares of Teva Pharmaceutical Industries Limited …
An investor, who purchased shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA), filed a lawsuit over alleged violations of Federal Securities Laws by Teva Pharmaceutical Industries Limited. Investors who purchased shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA) have certain options and for certain investors are short and strict deadlines running. Deadline: November 23, 2020. NYSE: TEVA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On
Investigation for Long-Term Investors in NYSE: TEVA shares over potential Wrongd …
Certain directors of Teva Pharmaceutical Industries Limited are under investigation concerning potential breaches of fiduciary duties. Investors who are current long term investors in Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: TEVA stocks follows a lawsuit filed against Teva Pharmaceutical Industries
Lawsuit filed for Investors in Teva Pharmaceutical Industries Limited (NYSE: TEV …
An investor, who purchased shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA), filed a lawsuit over alleged Securities Laws violations by Teva Pharmaceutical Industries Limited. Investors who purchased shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Israel based Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio
Global Atenolol Market 2016 - KOPRAN, Ipca, Teva
The report that is written on the titled Atenolol Market 2016 covers all the aspects of the global market study. This report has an estimation about the Atenolol Market size in terms of value (US$). The report contains the broad segmentation of the market. The report provides the information about the Atenolol Market and also forecasts its position in the coming years. Atenolol is a selective ß1 receptor antagonist, a
Global Doxorubicin Market 2017 By Key Manufacturers: Teva
The motive of this strategic research report entitled "Global Doxorubicin Market 2017" is to provide company officials, industry investors, and industry members with consequential insights to enable them make reliable strategic decisions regarding the opportunities in the global Doxorubicin market. Key Notes On Doxorubicin Market: "Global Doxorubicin Market 2017 "offers crucial insights into the global Doxorubicin market along with the market size and estimates for the duration 2017 to 2023. This industry report